1547 results about "Hydrazide" patented technology

The invention relates to a plant growth regulator composition containing maleic hydrazide and the purposes thereof. The composition contains maleic hydrazide (A) and a combination of known plant growth regulators, such as paclobutrazol, uniconazole, cycocel, mepiquat chloride, triapenthenol, daminozide, ethephon, taterpex and thidiazuron, wherein the weight ratio of the (A) to the (B) is 1: 300 to 500:1 and preferable 1:100 to 300:1, the (A) and the (B) can be proportioned with known aids and an excipient to prepare any agriculturally acceptable preparation; and the agriculturally acceptable preparation can be diluted with water or soil into a needed concentration of 1-8000 mg / kg, preferable 50-5000 mg / kg and used for regulating the growth of cultured plants, such as hedge plants, lawns, landscape plants, fruit trees, vegetables, economic crops, food oil crops and forage grass through the treatments of irrigation, flood irrigation, fertilization with water, jetting, spraying, scattering, smearing, injecting, transfusing, dressing seeds, spreading fertilizer, dispersing, and the like. The composition has the advantages of wide range of applications, low cost, good effect and synergy.

Substituted pyrazole compounds of the formula (1). The compounds are synthesized from a pyrazole derivative and a haloalkyleneoxime ester derivative, and have excellent herbicidal effects. Herbicide compositions containing the substituted pyrazole derivatives or hydrazide derivatives thereof as active ingredients possess wide herbicidal spectra, work sufficiently in small dosages, and are sufficiently safe for certain important crops

The present invention provides a non-radical photo-crosslinked hydrogel preparation method, comprising the following steps: a component A is dissolved in a biocompatible medium to obtain a solution A, component B-hydrazide, hydroxylamine or primary amine high molecular derivative is dissolved in a biocompatible medium to obtain a solution B; the solution A and the solution B are evenly mixed to obtain a hydrogel precursor solution; under illumination, aldehyde group produced by light excitation of o-nitrobenzyl in the component A of the hydrogel precursor solution is crosslinked with hydrazone, hydroxylamine or primary amine group in the component B in the form of respective formation of oxime and Schiff base to produce the hydrogel. The present invention also provides a kit for the hydrogel preparation, and application of the hydrogel in tissue repair, beauty and as a cell, protein or drug carrier. The tissue surface light-situ gel can be achieved by the hydrogel, in particular, wound surface in-situ thin glue formation can be achieved, and the hydrogel is especially suitable for clinical wound surface tissue repair and isolation.

The present invention relates to novel hydrazide-containing compounds of Formula I or Formula II, including pharmaceutically acceptable salts, esters, or prodrugs thereof which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

The present invention relates to an aqueous polyurethane coating composition comprising:1) 1 to 99 wt. % of the reaction product of:a) a polyol component, which is soluble or dispersible in water and is the reaction product of a polyisocyanate component containing 50 to 100 wt. % of an aliphatic diisocyanate, a polyol component containing one or more polyether polyols and having an OH number of 25 to 350 mg KOH / g solids and an isocyanate-reactive component containing at least one group capable of salt formation; andb) polyisocyanate component, which is soluble or dispersible in water, has blocked isocyanate groups and is the reaction product of one or more polyisocyanates having an isocyanurate group content of 2 to 30 wt. %, a reversible, monofunctional blocking agent for isocyanate groups, a nonionic hydrophilic component and a stabilizing component which has 1 to 2 hydrazide groups and a molecular weight of 70 to 300; and2) 1 to 99 wt. % of an aqueous polyurethane dispersion prepared from at least one polycarbonate polyol,wherein the total wt. % of components 1) and 2) add up to 100%.

Abstract of the Disclosure Methods for synthesis and manufacture of polysaccharide-protein conjugate vaccines at high yield are provided. The methods involve reaction of a hydrazide group on one reactant with an aldehyde or cyanate ester group on the other reactant. The reaction proceeds rapidly with a high conjugation efficiency, such that a simplified purification process can be employed to separate the conjugate product from the unconjugated protein and polysaccharide and other small molecule by-products.

Disclosed herein are compositions comprising a compound represented by structural formula (I): 2 g of which is reconstitutable in 10 mL of a water in less than 10 minutes, and methods for preparing these compositions. Also disclosed are compositions comprising a compound represented by structural formula (I) and a pharmaceutically acceptable excipient, wherein the molar ratio of said compound to said excipient is from 1:20 to 1:1, and methods for preparing these compositions.

Methods for the manufacture of polysaccharide-protein conjugate vaccines at high yield are provided. The methods involve reaction of a hydrazide group on one reactant with an aldehyde group on the other reactant. The reaction proceeds rapidly with a high conjugation efficiency. Simplified purification processes can be employed to separate the conjugate product from the unconjugated protein and polysaccharide and other small molecule by-products.

Disclosed is a method of preparing a thiohydrazide product compound from a hydrazide starting compound. The hydrazide starting compound is represented by Structural Formula (I):The thiohydrazide product compound is represented by Structural Formula (II):In Structural Formulas (I)–(II), R1 and R2 are independently an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or R1 and R2 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring. When R2 is an aryl group or a substituted aryl group, then R5 is a hydrazine protecting group; and when R2 is an aliphatic or substituted aliphatic group, then R5 is —H or a hydrazine protecting group. R10 is —H or a substituted or unsubstituted alkyl group. The method comprising the step of reacting the starting compound with a thionylating reagent.

The invention relates to a grease inhibitor for a caustic scrubbing tower of an ethylene plant and a method for using the same. The grease inhibitor consists of an alkylol amine compound, a hydrazide compound and an alkylamine compound. Moreover, the grease inhibitor not only overcomes the disadvantages of the prior inhibitor of high production cost, great toxicity and instable inhibition effect, but also effectively controls the output of grease inside the caustic scrubbing tower; meanwhile, the grease inhibitor reduces the discharge of waste lye and the consumption of fresh lye, and lightens the pressure on treating waste lye and environmental pollution caused by the grease.

Methods and medical devices for treating a proliferative disorder in a subject, e.g., restenosis in a blood vessel that has been implanted with a stent, employ a bis(thio-hydrazide amide) represented by Structural Formula I or a pharmaceutically acceptable salt or solvate thereof. Y is a covalent bond or an optionally substituted straight chained hydrocarbyl group, or, Y, taken together with both >C=Z groups to which it is bonded, is an optionally substituted aromatic group. R1-R4 are independently —H, an optionally substituted aliphatic group, an optionally substituted aryl group, or R1 and R3 taken together with the carbon and nitrogen atoms to which they are bonded, and / or R2 and R4 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring. R7-R8 are independently —H, an optionally substituted aliphatic group, or an optionally substituted aryl group. Z is O or S.

Disclosed herein are methods of treating a proliferative disease, such as cancer, with bis(thio-hydrazide amides) or a tautomer, pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, in combination with hyperthermia treatment. Also disclosed are methods of treating a proliferative disease, such as cancer, with bis(thio-hydrazide amides) or a tautomer, pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, in combination with radiotherapy.

Disclosed are bis(thio-hydrazide amide) disalts, which are represented by Structural Formula (I):Y is a covalent bond or a substituted or unsubstituted straight chained hydrocarbyl group. R1-R4 are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group, or R1 and R3 taken together with the carbon and nitrogen atoms to which they are bonded, and / or R2 and R4 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring. Z is —O or —S. M+ is a pharmaceutically acceptable monovalent cation and M2+ is a pharmaceutically acceptable divalent cation.Also, disclosed are pharmaceutical compositions comprising a bis(thio-hydrazide amide) disalt described above. Further disclosed are methods of treating a subject with cancer. The methods comprise the step of administering an effective amount of a bis(thio-hydrazide amide) disalt described above.

A versatile, eco-friendly, and efficient method for the convenient conversion of esters and ester-like compounds into amides, peptides, carbamates, ureas, oxamides, oxamates, hydrazides, oxazolidinones, pyrazolones, oxazolidinediones, barbituric acids, and other molecules containing one or more OCN moieties in the presence of a diol or polyol is disclosed.

Disclosed herein are methods of preventing or delaying the recurrence of melanoma in a subject with bis(thio-hydrazide amides) represented by a formula selected from Structural Formulas (I)-(IX) or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these bis(thio-hydrazide amides) and compositions comprising these bis(thiohydrazide)amides and one or more anti-cancer agent.

The invention discloses an efficient low-toxicity formaldehyde scavenger containing the following raw material components by weight: 0.5%-5% of hydrazide, 0.1%-5% of a water-soluble ester, 0.5%-10% of a moisture absorbent, 0.1%-0.5% and of a buffer, 0.05%-1% of a surface active agent, 0.02%-0.5% of a preservative and 80%-98% of water. The free hydrazine content in the efficient low-toxicity formaldehyde scavenger product is controlled in the range as low as possible by the manner of fine selection of the hydrazide raw material, control of free hydrazine content, adding of the water-soluble ester, adding of the buffer, and the like, and the efficient low-toxicity formaldehyde scavenger product has better security. The efficient low-toxicity formaldehyde scavenger product is good in formaldehyde removal effect, safe to people and objects, and simple in production process, and can be used for governance of the problem of formaldehyde exceeding the standard in new decorated residence or furniture.

There are provided a rubber composition having a high modulus of elasticity and a good workability, and a pneumatic tire.A rubber composition comprising at least one of natural rubber and synthetic diene rubbers as a rubber ingredient, at least one maleimide compound, and at least one nitrogen-containing compound selected from the group consisting of polyaniline, hydrazide, and amine compound is used in a tread.

The invention provides compositions, pharmaceutical preparations and methods for inhibition of cystic fibrosis transmembrane conductance regulator protein (CFTR) that are useful for the study and treatment of CFTR-mediated diseases and conditions. The compositions and pharmaceutical preparations of the invention may comprise one or more hydrazide-containing compounds, and may additionally comprise one or more pharmaceutically acceptable carriers, excipients and / or adjuvants. The methods of the invention comprise, in certain embodiments, administering to a patient suffering from a CFTR-mediated disease or condition, an efficacious amount of a hydrazide-containing compound. In other embodiments the invention provides methods of inhibiting CFTR that comprise contacting cells in a subject with an effective amount of a hydrazide-containing compound. In addition, the invention features a non-human animal model of CFTR-mediated disease which model is produced by administration of a hydrazide-containing compound to a non-human animal in an amount sufficient to inhibit CFTR.

The invention provides compositions, pharmaceutical preparations and methods for inhibition of cystic fibrosis transmembrane conductance regulator protein (CFTR) that are useful for the study and treatment of CFTR-mediated diseases and conditions. The compositions and pharmaceutical preparations of the invention may comprise one or more hydrazide-containing compounds, and may additionally comprise one or more pharmaceutically acceptable carriers, excipients and / or adjuvants. The methods of the invention comprise, in certain embodiments, administering to a patient suffering from a CFTR-mediated disease or condition, an efficacious amount of a hydrazide-containing compound. In other embodiments the invention provides methods of inhibiting CFTR that comprise contacting cells in a subject with an effective amount of a hydrazide-containing compound. In addition, the invention features a non-human animal model of CFTR-mediated disease which model is produced by administration of a hydrazide-containing compound to a non-human animal in an amount sufficient to inhibit CFTR.

A method of preparing a bis(thio-hydrazide amide) disalt includes the steps of combining a neutral bis(thio-hydrazide amide), an organic solvent and a base to form a bis(thio-hydrazide amide) solution; and combining the solution and methyl tert-butyl ether, thereby precipitating a disalt of the bis(thio-hydrazide amide). In some embodiments, a method of preparing a bis(thio-hydrazide amide) disalt includes the steps of combining a neutral bis(thio-hydrazide amide) and an organic solvent selected from methanol, ethanol, acetone, and methyl ethyl ketone to make a mixture; adding at least two equivalents of a base selected from sodium hydroxide, potassium hydroxide, sodium methoxide, potassium methoxide, sodium ethoxide and potassium ethoxide to the mixture, thereby forming a solution; and combining the solution and methyl tert-butyl ether to precipitate the disalt of the bis(thio-hydrazide amide). The disclosed methods do not require lyophylization and the solvents used in the process can be more readily removed to low levels consistent with pharmaceutically acceptable preparation.

Methods are described for conjugating radioiodinated peptides or carbohydrate structures to proteins with improved yields and qualities of conjugates. In one method, specially designed radioiodinated bifunctional peptides containing nonmetabolizable amide bonds are coupled to antibodies. In a second method, radioiodinated nonmetabolizable bifunctional peptides, which also contain aminopolycarboxylates, are coupled to antibodies. In a third method, radioiodinated bifunctional aminopolycarboxylates are coupled to antibodies. In a fourth method, a hydrazide-appended antibody is coupled to a radioiodinated carbohydrate or a thiolated antibody is coupled to a hydrazide-appended and radioiodinated carbohydrate. In a fifth method a monoderivatized cyanuric chloride is used to conjugate thiolated antibody. Radioiodinated residualizing antibody conjugates made by these methods are particularly stable in vivo and are suitable for radioimmunodetection and radioimmunotherapy.

Aluminum paste conductive glue and its production are disclosed. The glue consists of epoxy resin 10-20 proportion, acid anhydride curing agent 5-25 proportion, active diluting agent 1-10 proportion, curing improver 0.01-0.1 proportion, flake aluminum paste 5-85 proportion, grain aluminum paste 5-85 proportion. The process is carried out by curing at 120 degree for 30mins, and storing at room temperature for 3 months. The acid anhydride curing agent substitutes 1,3-diazole, dicyanodiamide, organic hydrazide or their modifiers as latent curing agent. It has excellent performances.

The invention discloses a quince preservative which is prepared by mixing cellulose, thiophanate methyl, carbendazim, p-hydroxybenzoic acid, vitamin C, maleic hydrazide and water. The invention has reasonable prescription, good preservation effect and low production cost. When in use, fruits are put in the preservative for 1 to 2 minutes.

Disclosed herein are methods of purifying a bis(thio-hydrazide amides) compounds of the following structural formula:wherein R1, R2, R3, R4, R7, R8, Z, and Y are defined herein.

The invention discloses a graphene oxide / hyaluronic acid nanometer drug carrier material. The graphene oxide / hyaluronic acid nanometer drug carrier material is characterized in that adipic acid hydrazide is covalently connected on the surface of monolayer graphene oxide, targeted molecular hyaluronic acid is further coupled by amino groups on the adipic acid hydrazide; the monolayer graphene oxide is 0.5-2nm thick; and the average size of the graphene oxide / hyaluronic acid nanometer drug carrier material is 50-300nm. According to the graphene oxide / hyaluronic acid nanometer drug carrier material provided by the invention, the hyaluronic acid is covalently modified on the surface of the graphene oxide and has a good targeting property; besides, the modified graphene oxide has good biocompatibility and benefits the biological application of the material; and moreover, the obtained functionalized nanometer material is expected to be used as a drug transmission carrier.

A rubber composition comprising 100 parts by weight of a rubber ingredient comprising natural rubber and / or a synthetic rubber, 0.1 to 50 parts by weight of at least one nitrogenous compound selected among benzimidazole derivatives having a specific structure and hydrazide derivatives having a specific structure, and 0.1 to 50 parts by weight of a protonic acid; and a pneumatic tire including a member formed from this rubber composition. The rubber composition enables excellent gripping performance while attaining intact productivity. The pneumatic tire produced from this rubber composition, in particular, the tire whose tread has been formed from the composition, has significantly improved gripping performance in high-speed driving, etc.

A composition of matter is disclosed wherein the composition comprises a hydrazide compound of the formula: wherein: R1 is selected from the group consisting of alkyl, alkyl ether, and phenyl; R2, R3, R4, R5, and R6 are independently selected from the group consisting of hydrogen, alkyl, alkyl ether, and aryl; and n is an integer of from 0 to 10; and wherein: when R1 is phenyl, it is of the structure: wherein R7, R8, and R9 are independently selected from the group consisting of hydrogen, alkyl, alkyl ether, and aryl, or R7 can be combined with R8 to form a ring of 5 or 6 carbon atoms. The hydrazides are useful as stabilizers for lubricants, greases, and polymeric systems, particularly lubricating oils, as are maleated polymers that have been functionalized with them.

The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula I:or a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and / or prevention of physiological conditions associated with CRM1 activity.